Annual CFF
$21.60 M
-$210.33 M-90.69%
December 31, 2024
Summary
- As of March 10, 2025, NMRA annual cash flow from financing activities is $21.60 million, with the most recent change of -$210.33 million (-90.69%) on December 31, 2024.
- During the last 3 years, NMRA annual CFF has fallen by -$271.90 million (-92.64%).
- NMRA annual CFF is now -92.64% below its all-time high of $293.51 million, reached on December 31, 2021.
Performance
NMRA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$15.57 M
+$14.04 M+917.18%
December 31, 2024
Summary
- As of March 10, 2025, NMRA quarterly cash flow from financing activities is $15.57 million, with the most recent change of +$14.04 million (+917.18%) on December 31, 2024.
- Over the past year, NMRA quarterly CFF has stayed the same.
- NMRA quarterly CFF is now -94.67% below its all-time high of $291.99 million, reached on September 1, 2021.
Performance
NMRA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$21.60 M
+$16.05 M+289.31%
December 31, 2024
Summary
- As of March 10, 2025, NMRA TTM cash flow from financing activities is $21.60 million, with the most recent change of +$16.05 million (+289.31%) on December 31, 2024.
- Over the past year, NMRA TTM CFF has stayed the same.
- NMRA TTM CFF is now -92.65% below its all-time high of $293.87 million, reached on September 1, 2021.
Performance
NMRA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
NMRA Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -90.7% | 0.0% | 0.0% |
| 3 y3 years | -92.6% | 0.0% | 0.0% |
| 5 y5 years | - | 0.0% | 0.0% |
NMRA Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -92.6% | at low | -93.3% | +3337.6% | -92.6% | +289.3% |
| 5 y | 5-year | -92.6% | at low | -94.7% | +3337.6% | -92.7% | +1642.2% |
| alltime | all time | -92.6% | at low | -94.7% | +3337.6% | -92.7% | +1642.2% |
Neumora Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $21.60 M(-90.7%) | $15.57 M(+917.2%) | $21.60 M(+289.3%) |
| Sep 2024 | - | $1.53 M(-42.3%) | $5.55 M(-97.6%) |
| Jun 2024 | - | $2.65 M(+43.8%) | $236.04 M(+1.0%) |
| Mar 2024 | - | $1.84 M(-483.6%) | $233.68 M(+0.8%) |
| Dec 2023 | $231.94 M(+100.4%) | -$481.00 K(-100.2%) | $231.94 M(-10.5%) |
| Sep 2023 | - | $232.02 M(>+9900.0%) | $259.25 M(+126.6%) |
| Jun 2023 | - | $292.00 K(+189.1%) | $114.40 M(-1.5%) |
| Mar 2023 | - | $101.00 K(-99.6%) | $116.19 M(+0.4%) |
| Dec 2022 | $115.74 M | $26.83 M(-69.2%) | $115.74 M(+30.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | $87.18 M(+4085.2%) | $88.55 M(-69.8%) |
| Jun 2022 | - | $2.08 M(-693.4%) | $293.36 M(+0.5%) |
| Mar 2022 | - | -$351.00 K(-2.0%) | $291.92 M(-0.5%) |
| Dec 2021 | $293.51 M(+27.6%) | - | - |
| Dec 2021 | - | -$358.00 K(-100.1%) | $293.51 M(-0.1%) |
| Sep 2021 | - | $291.99 M(>+9900.0%) | $293.87 M(>+9900.0%) |
| Jun 2021 | - | $640.00 K(-48.4%) | $1.88 M(+51.6%) |
| Mar 2021 | - | $1.24 M | $1.24 M |
| Dec 2020 | $230.10 M | - | - |
FAQ
- What is Neumora Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Neumora Therapeutics?
- What is Neumora Therapeutics annual CFF year-on-year change?
- What is Neumora Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Neumora Therapeutics?
- What is Neumora Therapeutics quarterly CFF year-on-year change?
- What is Neumora Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Neumora Therapeutics?
- What is Neumora Therapeutics TTM CFF year-on-year change?
What is Neumora Therapeutics annual cash flow from financing activities?
The current annual CFF of NMRA is $21.60 M
What is the all time high annual CFF for Neumora Therapeutics?
Neumora Therapeutics all-time high annual cash flow from financing activities is $293.51 M
What is Neumora Therapeutics annual CFF year-on-year change?
Over the past year, NMRA annual cash flow from financing activities has changed by -$210.33 M (-90.69%)
What is Neumora Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of NMRA is $15.57 M
What is the all time high quarterly CFF for Neumora Therapeutics?
Neumora Therapeutics all-time high quarterly cash flow from financing activities is $291.99 M
What is Neumora Therapeutics quarterly CFF year-on-year change?
Over the past year, NMRA quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Neumora Therapeutics TTM cash flow from financing activities?
The current TTM CFF of NMRA is $21.60 M
What is the all time high TTM CFF for Neumora Therapeutics?
Neumora Therapeutics all-time high TTM cash flow from financing activities is $293.87 M
What is Neumora Therapeutics TTM CFF year-on-year change?
Over the past year, NMRA TTM cash flow from financing activities has changed by $0.00 (0.00%)